Weill Cornell
C2i Genomics Lays Groundwork for Global Launch of Whole-Genome Minimal Residual Disease Test
Premium
With EU lab partnerships and a newly announced CE mark, the company is poised for the first clinical implementations of its solid tumor residual disease test.
Over the next year or so, the investigators plan to sequence the genomes of 3,000 patients with cancer, heart disease, diabetes, or neurological disorders.
Illumina, New York Healthcare Providers, NYGC Partner on Clinical Whole-Genome Sequencing
Weill Cornell Medicine, New York-Presbyterian Hospital, and the New York Genome Center will join Illumina to sequence the genomes of thousands of patients.
Routine Lab Tests Could Help Identify Patients With SARS-CoV-2
Weill Cornell Medicine researchers have developed a machine learning model that can identify patients likely infected with SARS-CoV-2 based on routine lab tests.
XPrize Competition Hopes to Encourage 'Frequent, Fast, Cheap, and Easy' COVID-19 Testing
The international competition's goal is to spark innovation and accelerate safe returns to work, school, and other public activities.